DexCom saw the highest growth of 3.05% in patent filings in May and 1.9% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.54% and grants by 1.9%. GlobalData’s DataBook provides a comprehensive analysis of DexCom‘s patent filings and grants. Buy the databook here.
DexCom has been focused on protecting inventions in United States(US) with 54 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 31% filings and 30% grants. The United States(US), Australia(AU), China(CN), and European Patent Office(EPO) patent Office are among the top ten patent offices where DexCom is filings its patents. Among the top granted patent authorities, DexCom has 30% of its grants in United States(US), 26% in Canada(CA) and 18% in European Patent Office(EPO).
Roche and Samsung Group could be the strongest competitors for DexCom
Patents related to healthtech and remote patient monitoring lead DexCom's portfolio
DexCom has the highest number of patents in healthtech followed by, remote patient monitoring and connected patient. For healthtech, nearly 20% of patents were filed and 18% of patents were granted in Q2 2024.
Healthcare it related patents lead DexCom portfolio followed by other remote patient monitoring, and electronic document mgmt
DexCom has highest number of patents in healthcare it followed by other remote patient monitoring, electronic document mgmt, glucose monitoring, and drug delivery devices. For healthcare it, nearly 19% of patents were filed and 11% of patents were granted in Q2 2024.
For comprehensive analysis of DexCom's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.